世界の再生医療市場：製品・治療法・用途・地域別 - 成長、動向、予測（2018年〜2023年）

世界の再生医療市場は、2018年から2023年にかけて14%のCAGRで推移し、2023年までに42億3,000万米ドルに達することが予測されています。地域別では、多くの先進技術を有する北米が最大市場となっています。

当レポートでは、世界の再生医療市場を調査し、市場の概要、技術タイプ・応用領域・地域別の市場動向、市場規模の推移と予測、市場シェア、市場促進・阻害要因ならびに市場機会・課題の分析、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 イントロダクション

• 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な推論

第5章 市場概要

• 現在の市場シナリオ
• ファイブフォース分析
  • 買い手の交渉力
  • 供給企業の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争企業間の敵対関係

第6章 市場力学

• 市場促進要因
  • 幹細胞技術の導入増加
  • 再生医療の技術的利点
• 市場阻害要因
  • 倫理的および規制上の問題
  • 治療費の高さと認識の低さ
• 市場機会
• 主な課題

第7章 世界の再生医療市場：市場区分

• 技術タイプ別
  • 幹細胞治療
  • 生体材料
  • 組織工学
• 応用領域別
  • 代替骨
  • 骨関節疾患
  • 皮膚
  • 心臓血管系
  • 中枢神経系
• 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • 中東・アフリカ
  • 南米

第8章 競合情勢

• M&A
• 協定、協力、提携
• 新製品の上市

第9章 主要企業

• ACELITY
• OSIRIS THERAPEUTICS
• INTEGRA LIFESCIENCES CORPORATION
• COOK BIOTECH INCORPORATED
• ORGANOGENESIS INC
• MERCK & CO
• その他の主要企業

第10章 市場の将来展望

The global regenerative medicine market has been estimated to reach USD 4.23 billion in 2023. The market is expected to register a CAGR of 14% during the forecast period 2018 to 2023. North America dominates the market due to the increasing technological advancements.

Increasing adoption of stem cell technology

Increasing adoption of stem cell technology, increasing prevalence of chronic diseases, emerging applications of gene therapy in regenerative medicine are some of the driving factors for Global Regenerative Medicine market. Technological advances in regenerative medicine (stem cell, tissue engineering, and nanotechnology) and high investment & funding to support development of regenerative medicine are also fuelling the market growth.

Regulatory and ethical issues

Regulatory and ethical issues pertaining stem cell, tissues engineering and regenerative medicine are acting as a restraint for Regenerative Medicine market. High cost of treatments and less awareness about the regenerative medicine among people is further restraining the market.

North America to Dominate the Market

The Regenerative Medicine market is segmented by type of treatment and geography. By geography it is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa and South America.

North America dominates the Regenerative Medicine market due to the increasing technological advancements and high investment & funding to support development of regenerative medicine. Asia-Pacific is also expected to propel the Regenerative Medicine market owing to factors, such as increasing accessibility to healthcare facilities in the region, and increasing economic growth.

Key developments in the market

In January, 2018: Medeor Therapeutics Awarded $18.8 Million From the California Institute for Regenerative Medicine

In January, 2018: RepliCel Life Sciences Inc. formed a partnership with the private firm, China-based Yofoto Health Industry Co. Ltd for regenerative medicine

Major key players: ACELITY, OSIRIS THERAPEUTICS, INC., INTEGRA LIFESCIENCES CORPORATION, ASTRAZENECA, COOK BIOTECH INCORPORATED, ORGANOGENESIS INC. and MERCK & CO., INC. etc.

Reasons to purchase this report

Market analysis for the Global Regenerative Medicine Market, with region-specific assessments and competition analysis on a global and regional scale.

Analyzing various perspectives of the company with the help of Porter's five forces analysis

The treatment type that is expected to dominate the market

Regions that are expected to witness fastest growth during the forecast period

Identify the latest developments, market shares and strategies employed by the major market players.

3 months analyst support along with the Market Estimate sheet in excel.

Customization of the report

This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.

Table of Contents

1. INTRODUCTION

• 1.1 MARKET DEFINITION

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. KEY INFERENCES

5. MARKET OVERVIEW

• 5.1 CURRENT MARKET SCENARIO
• 5.2 PORTER'S FIVE FORCES
• 5.2.1 BARGAINING POWER OF SUPPLIERS
• 5.2.2 BARGAINING POWER OF CONSUMERS
• 5.2.3 THREATS OF NEW ENTRANTS
• 5.2.4 THREAT OF SUBSTITUTE PRODUCT AND SERVICES
• 5.2.5 COMPETITIVE RIVALRY WITHIN THE INDUSTRY

6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)

• 6.1 MARKET DRIVERS
• 6.1.1 INCREASING ADOPTION OF STEM CELL TECHNOLOGY
• 6.1.2 TECHNOLOGICAL ADVANCES IN REGENERATIVE MEDICINE
• 6.2 MARKET RESTRAINTS
• 6.2.1 REGULATORY AND ETHICAL ISSUES
• 6.2.2 HIGH COST OF TREATMENTS AND LESS AWARENESS
• 6.3 OPPORTUNITIES
• 6.4 KEY CHALLENGES

7. MARKET SEGMENTATION

• 7.1 BY TYPE OF TECHNOLOGY
• 7.1.1 STEM CELL THERAPY
• 7.1.2 BIOMATERIAL
• 7.1.3 TISSUE ENGINEERING
• 7.2 BY TYPE OF APPLICATIONS
• 7.2.1 BONE GRAFT SUBSTITUTES
• 7.2.2 OSTEOARTICULAR DISEASES
• 7.2.3 DERMATOLOGY
• 7.2.4 CARDIOVASCULAR
• 7.2.5 CENTRAL NERVOUS SYSTEM
• 7.3 BY GEOGRAPHY
• 7.3.1 NORTH AMERICA
• 7.3.1.1 US
• 7.3.1.2 CANADA
• 7.3.1.3 MEXICO
• 7.3.2 EUROPE
• 7.3.2.1 FRANCE
• 7.3.2.2 UK
• 7.3.2.3 GERMANY
• 7.3.2.4 ITALY
• 7.3.2.5 SPAIN
• 7.3.2.6 REST OF EUROPE
• 7.3.3 ASIA-PACIFIC
• 7.3.3.1 INDIA
• 7.3.3.2 CHINA
• 7.3.3.3 JAPAN
• 7.3.3.4 AUSTRALIA
• 7.3.3.5 SOUTH KOREA
• 7.3.3.6 REST OF APAC
• 7.3.4 MIDDLE EAST AND AFRICA
• 7.3.4.1 GCC
• 7.3.4.2 SOUTH AFRICA
• 7.3.4.3 REST OF MIDDLE EAST AND AFRICA
• 7.3.5 SOUTH AMERICA
• 7.3.5.1 BRAZIL
• 7.3.5.2 ARGENTINA
• 7.3.5.3 REST OF SOUTH AMERICA

8. COMPETITIVE LANDSCAPE

• 8.1 MERGERS AND ACQUISITIONS
• 8.2 AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS
• 8.3 NEW PRODUCT LAUNCHES

9. KEY PLAYERS

• 9.1 ACELITY
• 9.2 OSIRIS THERAPEUTICS
• 9.3 INTEGRA LIFESCIENCES CORPORATION
• 9.4 COOK BIOTECH INCORPORATED
• 9.5 ORGANOGENESIS INC
• 9.6 MERCK & CO
• 9.7 OTHERS

10. FUTURE OUTLOOK OF THE MARKET